WebDec 28, 2024 · CULLINAN ONCOLOGY CONTACTS: Investors: Jeff Trigilio +1 716.725.5019 [email protected]. Media: Matt Burke +1 603.315.0618 … WebCullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to cancer patients. ... Cullinan Oncology Inc. Cullinan Oncology LLC. SIC Code 28,283. NAICS Code 32,325. Ticker NASDAQ: CGEM. Show More. Top …
Cullinan Oncology Completes $98.5 Million Series B Financing Cullinan …
WebCollaboration is key to how we work at Cullinan Oncology. The closer we work together—across teams, programs, backgrounds and experiences—the better we can … Cullinan Oncology has built a diversified pipeline by identifying high-impact … Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug … At Cullinan Oncology, our research is anchored in a deep understanding of … Zipalertinib (CLN-081/TAS6417) A Phase 1/2a, Open-label, multicenter, first-in … Taking a modality-agnostic approach offers incredible freedom to develop the most … www.cullinanoncology.com View our corporate presentation to learn more about Cullinan Oncology's goal of … WebCullinan Oncology is dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, … bobbleheads funny
Sr. Manager/ Associate Director, Clinical Supply Chain
WebFeb 14, 2024 · About Cullinan Oncology Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with … WebApr 15, 2015 · University of Minnesota. Aug 2009 - Dec 20095 months. Minneapolis, MN. •Prepared and purified targeted liposomes, and … WebCompany profile page for Cullinan Oncology LLC including stock price, company news, press releases, executives, board members, and contact information clinicalkey clonidine